A Phase II Study of Dasatinib (NSC 732517) in Previously-Treated Patients With Metastatic Colorectal Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Dasatinib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 19 May 2014 Biomarkers information updated
- 24 Aug 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Dec 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.